A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
Recruiting now · Phase 1/Phase 2
Conditions studied: B-cell Malignancy, Relapsed Cancer, Refractory Cancer, B-cell Lymphoma
In brief
The purpose of this study is to measure the safety, preliminary antitumor activity, pharmacokinetics, and pharmacodynamics with BGB-16673 in combination with other agents in participants with relapsed or refractory (R/R) B-cell malignancies. This study is structured as a master protocol with separate substudies. This study currently includes four substudies, and more substudies may be added as other combination agents are identified.
Key facts
- Study ID
- NCT06634589
- Run by
- BeOne Medicines
- People needed
- 80
- Starts
- 2024-11-27
- Expected to finish
- 2029-12-02
- Last updated by the study team
- 2026-07-23
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Mayo Clinic Phoenix — Phoenix, Arizona, United States (enrolling)
- University of Southern California Norris Comprehensive — Los Angeles, California, United States (enrolling)
- Mayo Clinic Jacksonville — Jacksonville, Florida, United States (enrolling)
- Moffitt Cancer Center — Tampa, Florida, United States (enrolling)
- The University of Kansas Cancer Center — Westwood, Kansas, United States (enrolling)
- Mayo Clinic Rochester — Rochester, Minnesota, United States (enrolling)
- Washington University School of Medicine — St Louis, Missouri, United States (enrolling)
- Summit Medical Group — Florham Park, New Jersey, United States (enrolling)
- Icahn School of Medicine At Mount Sinai — New York, New York, United States (enrolling)
- Columbia University Medical Center — New York, New York, United States (enrolling)
- Weill Cornell Medical College Newyork Presbyterian Hospital — New York, New York, United States (enrolling)
- Memorial Sloan Kettering Cancer Center Mskcc — New York, New York, United States (enrolling)
- University of Rochester — Rochester, New York, United States (enrolling)
- Fox Chase Cancer Center — Philadelphia, Pennsylvania, United States (enrolling)
- The University of Texas Md Anderson Cancer Center — Houston, Texas, United States (enrolling)
- Huntsman Cancer Institute — Salt Lake City, Utah, United States (enrolling)
- University of Wisconsin — Madison, Wisconsin, United States (enrolling)
- Medical College of Wisconsin — Milwaukee, Wisconsin, United States (enrolling)
- St George Hospital — Kogarah, New South Wales, Australia (enrolling)
- Mater Cancer Care Centre — South Brisbane, Queensland, Australia (enrolling)
- Monash Health — Clayton, Victoria, Australia (enrolling)
- Peter Maccallum Cancer Centre — Melbourne, Victoria, Australia (enrolling)
- The Alfred Hospital — Melbourne, Victoria, Australia (enrolling)
- Linear Clinical Research — Nedlands, Western Australia, Australia (enrolling)
- Hospital Sirio Libanes Brasilia — Brasília, Brazil (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.